1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2026

PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2026

  • July 2017
  • 377 pages
  • ID: 4149074
  • Format: PDF
  • By GlobalData

Summary

Table of Contents

Search Inside

PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2026

Summary
Type 2 diabetes (T2D) is a chronic disease characterized by insulin resistance and pancreatic ?-cell failure, with an underlying genetic predisposition heavily influenced by diet and lifestyle (Stumvoll et al., 2010). It is well recognized that many of the current therapies for T2D are generally unable to alter its natural course, with glycemic control typically deteriorating over time. This often results in increasingly complicated treatment regimens (Inzucchi et al., 2012). In the US, T2D is the leading cause of blindness, kidney failure, non-traumatic lower-limb amputations, cardiovascular disease (CVD), and mortality (Sarwar et al., 2010). It is a major cause of heart disease and stroke and is the seventh-leading cause of death among US adults.

Global Type 2 Diabetes (T2D) pharmaceutical market in the base year 2016 was $28.6B, including both branded and generic drugs. Branded products alone accounted for $23.8B across the 7MM. At 71% of the overall T2D market, the US is clearly the dominant market, totaling $20.3B in branded and generic pharmaceutical sales. This is due to the much higher prices of pharmaceuticals in this country and due to the highly diagnosed prevalence of T2D.

Over the forecast period of 2016-2026, the global T2D market will double, reaching $64.0B at a Compound Annual Growth Rate (CAGR) of 8.4%. The US will continue to grow in size most rapidly due to a dramatic increase in T2D prevalence and diagnosis, which is attributed to increased life expectancy and lifestyle changes. The US will increase its global market share from 71% to 74%, stealing market share predominantly from Japan, which will account for 9% of the overall T2D market in 2026. Sales in the US will grow by approximately 8.9% per year over the forecast period.

The report "PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2026" focuses on the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), also referred to as the “global market”.

This report provides the following information in-depth -
- Overview of T2D, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized T2D therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2016 and forecast for ten years to 2026.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the T2D therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global T2D therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report: Adocia, Astellas Pharma, AstraZeneca, Biocon, Boehringer Ingelheim, Bristol-Myers Squibb, Chong Kun Dang, Chugai Pharmaceuticals, Daiichi Sankyo, Diasome, Eli Lilly, GlaxoSmithKline, Intarcia Therapeutics, Ionis Pharmaceuticals, Johnson

Scope
- Overview of T2D, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized T2D therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2016 and forecast for ten years to 2026.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the T2D therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global T2D therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global T2D therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global T2D therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global T2D therapeutics market from 2016-2026.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
30% Off

($10995)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Type 2 Angiotensin II Receptor - Pipeline Review, H2 2019

Type 2 Angiotensin II Receptor - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Type 2 Angiotensin II Receptor - Pipeline Review, H2 2019SummaryType 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Angiotensin II receptor type 2 (AT2 receptor) is a protein encoded ...

Tyrosine Protein Phosphatase Non Receptor Type 1 - Pipeline Review, H2 2019

Tyrosine Protein Phosphatase Non Receptor Type 1 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Tyrosine Protein Phosphatase Non Receptor Type 1 - Pipeline Review, H2 2019SummaryTyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental ...

Familial Amyloid Neuropathies - Pipeline Review, H2 2019

Familial Amyloid Neuropathies - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Familial Amyloid Neuropathies - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Familial Amyloid Neuropathies - Pipeline Review, H2 2019, provides an overview ...


ref:plp2017

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on